Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 beta--lactamase-producing Klebsiella pneumoniae epidemic clone.

Abstract

We report the use of tigecycline, firstly with colistin and finally alone, in a patient with a persistent breakthrough bacteremia due to a Klebsiella pneumoniae isolate harboring a metallo-beta-lactamase (VIM-1) and an extended-spectrum beta-lactamase (SHV-12). Time-kill studies demonstrated that the combination of both compounds was synergistic along the first 12 h, suppressing the regrowth observed after 3 to 6 h when colistin was tested alone.

• Authors: Javier Cobo, María-Isabel Morosini, Vicente Pintado, Marta Tato, Noemí Samaranch, Fernando Baquero, Rafael Cantón
• Journal: Diagnostic microbiology and infectious disease (Diagn Microbiol Infect Dis) Vol. 60 Issue 3 Pg. 319-22 (Mar 2008) ISSN: 0732-8893 [Print] United States
• PMID: 17996417 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Bacterial Agents
• Tigecycline
• beta-Lactamases
• Minocycline
• Colistin

Topics

• Aged
• Anti-Bacterial Agents (therapeutic use)
• Bacteremia (drug therapy)
• Colistin (therapeutic use)
• Drug Synergism
• Drug Therapy, Combination
• Humans
• Klebsiella Infections (drug therapy)
• Klebsiella pneumoniae (drug effects, enzymology)
• Male
• Microbial Sensitivity Tests
• Microbial Viability
• Minocycline (analogs & derivatives, therapeutic use)
• Tigecycline
• beta-Lactamases (biosynthesis)